Hypothesis

Intermittent fasting does not merely raise NAD+ levels to counteract senescence; it actively re‑programs the senescence‑associated secretory phenotype (SASP) by boosting NAD+-dependent SIRT6 activity, which remodels chromatin at pro‑inflammatory loci and breaks the CD38‑driven NAD+ consumption loop.

Mechanistic Basis

The NAD+ decline observed in aging is amplified by senescent cells that secrete SASP factors, inducing CD38 expression and consuming NAD+ Senescent cells induce CD38 via SASP. Low NAD+ stabilizes HIF‑1α, creating a pseudohypoxic state that further impairs mitochondrial function HIF‑1α stabilization by NAD+ loss. This creates a vicious cycle where NAD+ loss fuels more senescence.

We propose that the NAD+ surge generated during a 48‑hour fast activates the salvage enzyme NAMPT, raising intracellular NAD+ 40‑60% Fasting elevates NAD+ via NAMPT. The increased NAD+ allosterically enhances SIRT6 deacetylase activity. SIRT6 removes acetyl groups from histone H3K9 at NF‑κB target promoters, promoting a more compact chromatin state and reducing transcription of IL‑6, IL‑1β and other SASP components SIRT6 deacetylates chromatin at inflammatory genes. Concurrently, fasting‑induced autophagy clears damaged mitochondria, lowering ROS‑driven DNA damage that would otherwise trigger PARP‑mediated NAD+ consumption Autophagy contributes to mitochondrial turnover.

By simultaneously increasing NAD+ production and directing it toward SIRT6‑mediated chromatin repression, fasting shifts the cellular budget from a "damage‑control" mode to a "maintenance" mode. The restored NAD+/NADH ratio also improves nuclear‑mitochondrial communication by reducing HIF‑1α stabilization, thereby improving oxidative phosphorylation Restoring NAD+ rescues colon degeneration.

Testable Predictions

1. NAD+ and SIRT6 activity – In human peripheral blood mononuclear cells subjected to a 48‑hour fast, NAD+ levels will rise ≥40% and SIRT6‑dependent deacetylation of H3K9ac at the IL6 promoter will increase ≥2‑fold compared with fed controls (measured by Western blot and ChIP‑qPCR).
2. SASP suppression – The same fasting protocol will reduce secreted IL‑6, IL‑8 and MMP‑3 concentrations in the supernatant by ≥50% (ELISA). This reduction will be abolished in cells pre‑treated with the SIRT6 inhibitor MC‑1568 or in CD38‑overexpressing cells, indicating that SIRT6 activity downstream of NAD+ is required for SASP attenuation.
3. Reversal of senescence markers – Fasting will decrease the proportion of p16^INK4a^‑positive and SA‑β‑gal‑positive cells in aged human dermal fibroblasts by ~30% after 48 h, an effect that disappears when NAMPT is knocked down with siRNA, confirming that NAD+ synthesis is necessary.
4. In vivo validation – Old mice subjected to biweekly 48‑hour fasts for 8 weeks will show colonic epithelial NAD+ levels restored to youthful levels, reduced crypt hyperplasia, and lower colonic CD38 immunostaining compared with ad libitum fed controls. Parallel SIRT6 liver‑specific knockout mice will fail to exhibit these improvements, linking the phenotype to SIRT6 activity.

Implications

If validated, this hypothesis reframes NAD+ not as a passive biomarker of aging but as an active regulatory node that fasting exploits to reset epigenetic inflammatory programming. It suggests that timed NAD+ boosting strategies—combining fasting, NAMPT activators, and SIRT6 agonists—could be more effective than NAD+ supplementation alone for mitigating age‑related inflammation and tissue dysfunction.